<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098691</url>
  </required_header>
  <id_info>
    <org_study_id>KAEK/2020.05.13</org_study_id>
    <nct_id>NCT05098691</nct_id>
  </id_info>
  <brief_title>Early Onset Preeclampsia and Nectin-4</brief_title>
  <official_title>Serum Nectin-4 Levels in Patients With Early Onset Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hatice Akkaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kayseri Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early-onset Preeclampsia (PE) is a pregnancy disorder which may present with adverse&#xD;
      pregnancy outcomes. Nectin-4 is an adhesion molecule mainly expressed in placenta. This study&#xD;
      aimed to evaluate the relationship between early onset Preeclampsia and serum Nectin 4&#xD;
      levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preeclampsia is assumed as a two-stage disorder arising from defective trophoblast invasion&#xD;
      and failure of spiral artery remodeling as the main step responsible for the pathogenesis. PE&#xD;
      is classified according to the disease onset time as early-onset PE before 34 weeks and&#xD;
      late-onset PE after 34 weeks. Late-onset PE is more commonly seen and accepted as a mild&#xD;
      maternal reaction to pregnancy. In early-onset PE, unlike the late-onset, due to the improper&#xD;
      placental invasion, the diffuse placental ischemia and the resulting oxidative stress begin&#xD;
      at early gestation. Thus, the early-onset PE may result in severe disease leading to&#xD;
      perinatal and maternal morbidity and mortality.&#xD;
&#xD;
      The nectins are calcium-independent immunoglobulin-like celladhesion molecules and have a&#xD;
      pivotal role at cellular junctions, as well as physiological regulations(8). Placenta&#xD;
      expressesfor types of nectins; nectin-1, nectin-2, nectin-3, and nectin-4. They are localized&#xD;
      at tight junctions and gap junctions of syncitiotrophoblasts(9). Nectin-4 is a relatively&#xD;
      novel member of nectin family which has been detected only in placenta and airway epithelium&#xD;
      in healthy subjects.&#xD;
&#xD;
      Despite, there has been no study published yet to reveal the soluble nectin-4 levels in&#xD;
      preeclampsia as well as in early onset disease. In this study, we aimed to investigate the&#xD;
      serum nectin-4 levels in early-onset preeclampsia in comparison of the healthy pregnancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum nectin-4 levels</measure>
    <time_frame>1 hour</time_frame>
    <description>ng/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI (body mass index)</measure>
    <time_frame>5 minute</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tansion Arterial</measure>
    <time_frame>5 minute</time_frame>
    <description>mm Hg</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">84</enrollment>
  <condition>Pre-Eclampsia</condition>
  <condition>Early Onset Preeclampsia</condition>
  <condition>Oxidative Stress</condition>
  <condition>Immunologic Diseases in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Group 1 (Early onset Preeclampsia )</arm_group_label>
    <description>43 cases The groups were matched for gestational age and gravidity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 ( Healthy pregnant woman) control group</arm_group_label>
    <description>41 cases The groups were matched for gestational age and gravidity</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum marker levels</intervention_name>
    <description>two groups comparisons</description>
    <arm_group_label>Group 1 (Early onset Preeclampsia )</arm_group_label>
    <arm_group_label>Group 2 ( Healthy pregnant woman) control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Comparison to the level of soluble nectin-4 in early-onset PE, compared to healthy&#xD;
        pregnancies&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  spontaneous,&#xD;
&#xD;
          -  singleton pregnancies&#xD;
&#xD;
          -  above the 24 weeks of gestations&#xD;
&#xD;
          -  positive fetal cardiac activity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multiple gestations,&#xD;
&#xD;
          -  chronic hypertension&#xD;
&#xD;
          -  hypothyroidism&#xD;
&#xD;
          -  known malignancy,- diabetes mellitus,&#xD;
&#xD;
          -  presence of fetal or maternal infection,&#xD;
&#xD;
          -  clinical signs of chorioamnionitis (maternal fever, vaginal discharge, fetal&#xD;
             tachycardia),&#xD;
&#xD;
          -  hepatic or renal failure&#xD;
&#xD;
          -  Placenta previa or pregnancies accompanied congenital fetal abnormalities or&#xD;
             aneuploidies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hatice Akkaya</name>
      <address>
        <city>Ä°stanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 16, 2021</study_first_submitted>
  <study_first_submitted_qc>October 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kayseri Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Hatice Akkaya</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>early onset preeclampsia</keyword>
  <keyword>nectin-4</keyword>
  <keyword>advers pregnancy outcome</keyword>
  <keyword>hypertansion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>If needed</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>1 year</ipd_time_frame>
    <ipd_access_criteria>journals editors request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

